Compare Incyte Corporation (INCY) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Prudential PLC — how do they compare? Incyte Corporation trades at $120.7 (market cap $24.54B), while Prudential PLC trades at $27.52 (market cap $34.02B). The key difference: Prudential PLC is the larger of the two by market cap, and Prudential PLC pays a 1.94% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PUK | |
|---|---|---|
Market Cap | $24.54B | $34.02B |
Sector | Health | Financials |
52-Week High | $129.93 | $33.61 |
52-Week Low | $81.61 | $24.98 |
Enterprise Value | $20.04B | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Prudential PLC (PUK) trades at $27.48, down 2.62% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and recent earnings beats. Revenue grew to $16.21B in 2024, with net income of $2.29B, while cash flow from operations surged to $3.61B. Recent news highlights a dividend declaration and strategic acquisitions, but shares face pressure from China regulatory concerns.
The outlook is mixed: attractive valuation and profitability support upside, but bearish technicals and China-related risks pose headwinds. Analyst consensus leans buy (50%), with institutional focus on execution of cost-cutting and geographic strategy. Key risks include regulatory changes in Asia and market volatility impacting near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
